Compagnie Lombard Odier SCmA’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,000	Closed	-$2K	–	913
2016 Q4	$2K	Hold	1,000	–	–	﹤0.01%	795
2016 Q3	$3K	Hold	1,000	–	–	﹤0.01%	886
2016 Q2	$4K	Hold	1,000	–	–	﹤0.01%	869
2016 Q1	$6K	Hold	1,000	–	–	﹤0.01%	918
2015 Q4	$17K	Hold	1,000	–	–	﹤0.01%	815
2015 Q3	$21K	Hold	1,000	–	–	﹤0.01%	696
2015 Q2	$50K	Hold	1,000	–	–	﹤0.01%	645
2015 Q1	$78K	Buy	+1,000	New	+$62K	﹤0.01%	709

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Compagnie Lombard Odier SCmA's OREX Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 1,000 shares — an estimated $2K sold.

Compagnie Lombard Odier SCmA first reported a position in OREX in Q1 2015 and held it in 8 quarters. The position peaked at $78K in Q1 2015. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

Compagnie Lombard Odier SCmA reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 1,000 Orexigen Therapeutics, Inc. shares in Q1 2017, an estimated $2K.
Compagnie Lombard Odier SCmA first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
Compagnie Lombard Odier SCmA's Orexigen Therapeutics, Inc. position peaked at $78K in Q1 2015.
52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.